Login / Signup

Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study.

Dehua LiaoMinghui LongJiwen ZhangXingyu WeiFei LiTing YanDesong Yang
Published in: Lung cancer (Amsterdam, Netherlands) (2024)
Pralsetinib demonstrated promising activity in patients with advanced NSCLC harboring RET fusion with a favorable safety profile.
Keyphrases
  • small cell lung cancer
  • advanced non small cell lung cancer
  • cross sectional
  • epidermal growth factor receptor
  • tyrosine kinase